Stelara; Stelara antibodies
Ustekinumab Quantitation with Antibodies, Serum
Test
Aliases/Synonyms
Method
ELISA
Method Description
Ustekinumab (UTK) quantitation and anti-ustekinumab antibody measurements are performed using enzyme-linked immunosorbent assay. Microwell strips are pre-coated with UTK or anti-UTK antibody . Calibrators, controls, and patient samples are added to separate wells, allowing either UTK or antibodies to ustekinumab (ATUs) to bind to immobilized antigen. Unbound sample is washed away, and a second horseradish peroxidase-labeled anti-UTK or UTK (conjugate) is added to each well. A second incubation step allows the conjugate to bind to the UTK or ATU that has become attached to the microwells. After washing away the excess of unbound conjugate, the remaining enzyme activity is determined by adding a substrate and measuring the intensity of the color that develops in a spectrophotometer. The signal obtained is proportional to the amount of UTK or ATUs in the patient sample.
Report Includes
Ustekinumab; Ustekinumab Antibodies
Specimens
Serum
Clinical Utility
Evaluation of loss of response to therapy.
Quantification of ustekinumab in human serum.
Trough level quantitation for evaluation of patients treated with ustekinumab.
Detection of antibodies to ustekinumab in human serum.
Test Version
19-Nov-2025
Specimen
Specimens
Serum
Collection Containers
Preferred
Gold top (clot activator & gel)
Acceptable
Red top (no additive)
Sample Volume
0.5 mL
Minimum Volume
0.35 mL
Patient Preparation
Collect specimen immediately before the next dose of drug administration (trough level).
Collection & Handling
Handling Information
Store and send cold or frozen.
Stability
| Refrigerated | 21 days |
|---|---|
| Frozen | 21 days |
Rejection Criteria
| Specimen | Heat Inactivated |
|---|
Test Version
19-Nov-2025
Performance / Interpretation
Method
ELISA
Method Description
Ustekinumab (UTK) quantitation and anti-ustekinumab antibody measurements are performed using enzyme-linked immunosorbent assay. Microwell strips are pre-coated with UTK or anti-UTK antibody . Calibrators, controls, and patient samples are added to separate wells, allowing either UTK or antibodies to ustekinumab (ATUs) to bind to immobilized antigen. Unbound sample is washed away, and a second horseradish peroxidase-labeled anti-UTK or UTK (conjugate) is added to each well. A second incubation step allows the conjugate to bind to the UTK or ATU that has become attached to the microwells. After washing away the excess of unbound conjugate, the remaining enzyme activity is determined by adding a substrate and measuring the intensity of the color that develops in a spectrophotometer. The signal obtained is proportional to the amount of UTK or ATUs in the patient sample.
Turnaround Time
9 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| Ustekinumab quantification | mcg/mL |
|
||
| Ustekinumab Antibodies | AU/mL |
|
||
Test Version
19-Nov-2025
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| USQA S | 65235Ustekinumab QN, S | mcg/mL |
| 65236Ustekinumab Ab, S | AU/mL |
Test Version
19-Nov-2025